Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapropterin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAH known ✓ | P00439 | 1/20 | 0.81 |
| ▸ | NOS1 | P29475 | 10/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | NOS3 | P29474 | 3/20 | 0.62 |
| ▸ | NOS2 | P35228 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapropterin SCHEMBL21068033 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL4217501 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29538547 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29351671 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL7942378 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL260185 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL14401407 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29059706 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL31106620 | 0.99 | KDM4E (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL1070424 | 0.99 | KDM4E (1.00) | NOS1CASP7HSD17B10USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | PAH 2139/4885NOS1 2064/4885CASP7 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.